3651 results for «301»

Filter By

3651 results

Optimising immediate and long-term outcomes after TAVI

29 Nov 2022 – From PCR London Valves 2022

This session addresses three important topics that impact post-procedural and long-term outcomes after performing TAVI: the impact of permanent pacemaker rates and paravalvular leak, the importance of neo-commissural alignment, and the role of cerebral embolic protection.

Optimising immediate

Valve-in-valve interventions

27 Nov 2022 – From PCR London Valves 2022

The 8 videos in this PCR LV 2022 session on ViV procedures will allow you to learn more about ultrasound imaging for BASILICA procedure optimization in ViV TAVI, or compare coronary access between 2 self-expandable TAVI in degenerated surgical bioprosthesis, and much more!

Valve-in-valve interventions

The right valves for the right ventricle: Venus MedTech tricuspid and pulmonary replacement systems

27 Nov 2022 – From PCR London Valves 2022

In this session from PCR London Valves 2022, discover the new Venus MedTech technology for tricuspid and pulmonary valve replacement, and a review of the clinical indications, selection criteria and procedural details.

The right valves for the right ventricle: Venus MedTech tricuspid and pulmonary replacement systems

Valve-in-valve TAVI: session 1

27 Nov 2022 – From PCR London Valves 2022

ViV TAVI in a patient with previous Bentall's operation, ViV for a failed surgical aortic bioprosthesis with a misaligned mitral bioprosthesis, TAVI for severe aortic regurgitation caused by infective endocarditis after homograft surgery, and much more in this PCR LV 2022 session about ViV TAVI!

Valve-in-valve TAVI: session 1

Therapy of valvular heart diseases: a patient-centred innovation journey

27 Nov 2022 – From PCR London Valves 2022

Join a team of experts as they review together the complete spectrum of valvular heart disease and ways in which we can manage it using emerging novel technologies.

Therapy of valvular heart

TAVI complications: Session 1

27 Nov 2022 – From PCR London Valves 2022

Consult this session to discover a selection of challenging TAVI complications cases: an annular rupture after TAVI in a bicuspid aortic valve, an outflow tract rupture during self-expandable transcatheter valve implantation, a periprocedural TAVI ischaemic stroke, and more!

TAVI complications: Session 1

Reinventing the treatment of patients with tricuspid valve disease

28 Nov 2022 – From PCR London Valves 2022

This innovative session takes you through the patient selection and anatomical characteristics when selecting amongst the different transcatheter options to treat tricuspid regurgitation, followed by a recorded demonstration using the PASCAL Precision repair system.

Reinventing the treatment

Rapid-fire abstracts: session 1

27 Nov 2022 – From PCR London Valves 2022

Watch this PCR LV 2022 session to get clinical outcomes after TAVR in obese and non-obese patients with small aortic annuli, to find out how non-calcific aortic valve tissue quantified from coronary CT angiography can predict one-year mortality post-TAVI, and even more!

Rapid-fire abstracts: session 1

The PASCAL IID Registry: A prospective registry for transcatheter edge-to-edge repair in prohibitive risk patients with degenerative mitral regurgitation and complex mitral valve anatomy

17 Sep 2022

Alex Sticchi provides his take on the PASCAL IID Registry and an initial comparison with the CLASP IID. The trial was presented by Jörg Hausleiter during TCT Congress 2022.

Alessandro Sticchi

Author

Alessandro Sticchi
The PASCAL IID Registry: A Prospective Registry for Transcatheter Edge-to-Edge Repair in Prohibitive Risk Patients With Degenerative MR and Complex Mitral Valve Anatomy

Long-term beta-blocker treatment after acute myocardial infarction and preserved left ventricular ejection fraction: The REDUCE-AMI Trial

07 Apr 2024

REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.

Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...

Nicola Ryan

Author

Nicola Ryan

Author

Ali Nazmi Calik
REDUCE-AMI: Long-term beta-blocker treatment after AMI and preserved LVEF

SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk

07 Nov 2021

Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...

Paola Redaelli

Author

Paola Redaelli
M. Pighi

Author

Michele Pighi
SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk
Didn’t find what you were looking for?